Figure 6
sTRM deficiency resulted in rechallenged tumor progression. (A) Experimental description of multiple tumors inoculation in the absence of peripheral T cells. Briefly, the DEREG mice that have rejected CMS5 tumors by Tregs depletion were injected i.p. with 200 μg anti-CD3ε F(ab′)2 fragment antibodies once a week. Mice were rechallenged with CMS5 tumors in the right, left flank, and neck of the back, respectively (CMS5-1, CMS5-2, and CMS5-3). The littermate WT mice injected with T cells depletion antibodies and challenged with multiple tumors were as control. Tumor growth was monitored (B–E) (n = 5). (F) Illustration of an experimental procedure to observe the rechallenged CMS5 tumors development with sTRM cell depletion. Tumor cells were injected in the right flank. And anti-CD3ε F(ab′)2 fragment antibodies were injected 100 μg i.p. and 100 μg i.d. in the right flank weekly. (G) Tumor growth was monitored (n = 5). Two-way ANOVA followed by multiple comparisons for tumor growth curve analysis was used. Error bars represent mean ± SEM.
